Hyperfine, Inc. Stock

Equities

HYPR

US44916K1060

Advanced Medical Equipment & Technology

Delayed Nasdaq 10:25:24 2024-04-30 am EDT 5-day change 1st Jan Change
0.82 USD 0.00% Intraday chart for Hyperfine, Inc. +0.12% -26.79%
Sales 2024 * 12.79M Sales 2025 * 16.19M Capitalization 59.05M
Net income 2024 * -37M Net income 2025 * -35M EV / Sales 2024 * 4.62 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 3.65 x
P/E ratio 2024 *
-1.58 x
P/E ratio 2025 *
-1.64 x
Employees 131
Yield 2024 *
-
Yield 2025 *
-
Free-Float 69.58%
More Fundamentals * Assessed data
Dynamic Chart
Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study CI
Wells Fargo Trims Hyperfine's Price Target to $1.60 From $2.10, Keeps Equalweight Rating MT
B. Riley Trims Hyperfine's PT to $1.30 From $1.70 After 'Disappointing' Q4 2023 Sales, 2024 Guidance; Maintains Buy Rating MT
Transcript : Hyperfine, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Earnings Flash (HYPR) HYPERFINE Posts Q4 Revenue $2.7M MT
Hyperfine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Hyperfine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hyperfine, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 CI
Hyperfine, Inc. and Athletic Heart Cardiac and Metabolic Testing, Llc Announce Collaboration to Bring Portable Brain Imaging Screening to Current and Former Professional Athletes CI
Hyperfine, Inc. Launches AI-Powered Brain Imaging Software for Enhanced Image Quality and Ease of Use CI
Jefferies Starts Hyperfine With Hold Rating MT
Transcript : Hyperfine, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Hyperfine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (HYPR) HYPERFINE Reports Q3 Revenue $2.3M, vs. Street Est of $2.95M MT
Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2023 CI
More news
1 day-2.96%
1 week-3.53%
Current month-18.00%
1 month-18.00%
3 months-24.77%
6 months-29.91%
Current year-26.79%
More quotes
1 week
0.80
Extreme 0.8
0.89
1 month
0.80
Extreme 0.7951
1.08
Current year
0.80
Extreme 0.7951
1.39
1 year
0.80
Extreme 0.7951
3.28
3 years
0.68
Extreme 0.68
16.61
5 years
0.68
Extreme 0.68
16.61
10 years
0.68
Extreme 0.68
16.61
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 21-12-21
Director of Finance/CFO 49 23-02-12
Chairman 59 21-06-14
Members of the board TitleAgeSince
Founder 60 14-02-24
Chief Executive Officer 58 21-12-21
Director/Board Member 71 21-12-21
More insiders
Date Price Change Volume
24-04-30 0.82 0.00% 27 461
24-04-29 0.82 -2.96% 55,048
24-04-26 0.845 +1.68% 27,227
24-04-25 0.831 +2.59% 21,996
24-04-24 0.81 -1.10% 69,428

Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT

More quotes
Hyperfine, Inc. is a health technology company. The Company provides a Swoop Portable Magnetic Resonance Imaging System (Swoop system), which is a portable magnetic resonance imaging (MRI) system capable of providing neuroimaging at the point of care. Its Swoop system produces images at a lower magnetic field strength than conventional MRI scanners. The Swoop system is a portable, ultra-low-field (ULF) MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. MRI is used in various clinical settings for medical diagnosis, the staging of disease, and follow-up treatment. It has designed Swoop system to address an unmet need in point-of-care medical imaging through a combination of hardware and artificial intelligence (AI)-powered software services. The Company’s system operates from a Wi-Fi-capable tablet and integrates with picture archiving and communication systems (PACS).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.82 USD
Average target price
1.3 USD
Spread / Average Target
+58.54%
Consensus